Core Insights - BioNxt Solutions Inc. has signed a non-binding letter of intent (LOI) for exclusive negotiations regarding the commercialization of its sublingual cladribine oral thin film (ODF) product in the Eurasian Patent Organization (EAPO) member states following recent patent grants in Eurasia and Europe [1][2][4] Patent Protection and Commercialization Strategy - The LOI outlines a structured pathway for a potential regional licensing arrangement, enhancing BioNxt's global intellectual property position [2][3] - BioNxt has secured patent protection for its cladribine ODF formulation from both the EAPO and the European Patent Office (EPO), valid through at least June 14, 2043 [6][8] - The EAPO patent covers sublingual delivery of therapeutic compounds, providing protection in eight member states with a combined population exceeding 200 million [7][9] Market Opportunity - The Eurasian region's population offers significant demographic reach for the commercialization of innovative therapies, while the European patent is expected to cover up to 39 jurisdictions, enhancing market access [9][10] - The global needle-free drug delivery market was valued at approximately USD 14.39 billion in 2024 and is projected to reach approximately USD 30.73 billion by 2032, indicating a growing demand for patient-centric drug delivery solutions [13][14] Development Pathway - BioNxt's development focus is on demonstrating bioequivalence of its sublingual formulation compared to existing tablet products, with preparations for a human bioequivalence study underway [15][16] - The company aims to leverage its differentiated, IP-protected delivery system to reduce development risk and enable an accelerated commercialization strategy [14][16]

Core Viewpoint - Nasus Pharma is set to present data on its investigational intranasal epinephrine powder formulation, NS002, at the AAAAI 2026 Annual Meeting, highlighting its potential for superior absorption and stability compared to traditional liquid formulations [1][2]. Group 1: Product Development - NS002 is designed as a needle-free intranasal powder aimed at delivering epinephrine rapidly in emergency situations, particularly for anaphylaxis treatment [2][4]. - The product utilizes proprietary powder-based intranasal (PBI) technology, which leverages the nasal cavity's vascular network for quick absorption, potentially offering faster and higher absorption rates than liquid-based nasal products [4]. Group 2: Presentation Details - The presentation titled "Nasal epinephrine spray for anaphylaxis: which is better - powder or liquid?" will showcase that nasal powder has significantly higher deposition in the nasal cavity compared to liquid nasal spray, which could enhance blood absorption [3]. - Another presentation will focus on the stability of FMXIN002 Epinephrine Intranasal Powder Spray throughout three freeze-thaw cycles, indicating its robustness [3]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions, with NS002 being a key candidate for anaphylaxis treatment [4].

Core Insights - NuGen Medical Devices Inc. is developing a next-generation needle-free injection system aimed at improving drug delivery technology, protected under international patent WO2021206553 [1][2] - The new system integrates a sterile internal insulin cartridge into the needle-free autoinjector, eliminating the need for external connectors and reducing dosing errors and contamination risks [2][6] - The innovation is expected to enhance patient experience for those requiring daily injections, positioning it as a competitor to pen-based injectors [3] Technical Highlights - The internal cartridge integration streamlines the injection process by removing the need for external adaptors and manual filling [6] - A backflow control mechanism is included to ensure precise and safe insulin delivery, addressing unique challenges of jet injection [6] - Improved usability is a focus, simplifying operation for patients and caregivers, which is anticipated to reduce training time and improve compliance [6] Future Milestones - NuGen plans to begin clinical investigations using its currently approved needle-free platform, allowing for parallel development of the new cartridge-based system [6] - The company aims to produce working prototypes within six months to showcase the technology and conduct usability studies [6] - Full tooling investment for scaled manufacturing and commercialization is expected to commence in early 2026 [6] Company Overview - NuGen Medical Devices specializes in next-generation needle-free devices for subcutaneous drug delivery, with its flagship InsuJet™ system approved in 42 countries [5]